Shares of Pfizer fell 3.89% to $39.52 at 14:22 EST on Monday, after three successive sessions in a row of losses. The New York Stock Exchange is falling 0.37% to $14,301.50, following yesterday’s downward trend, This seems, up until now, a somewhat rough trend exchanging session today.

Pfizer’s last close was $41.12, 9.01% under its 52-week high of $43.08.

News about Pfizer today

Pfizer May offer shots to trial volunteers who received placebo. According to today’s article on Bloomberg Quint, “”Pending required approvals, Pfizer and BioNTech plan to provide an option for clinical trial participants who received the placebo to get the vaccine at scheduled time points in the study,” Pfizer said in an emailed statement. “, “Pfizer Inc. and BioNTech SE may soon allow participants in its Covid-19 vaccine trial to learn whether they received a placebo, rather than the real thing, and get the actual shot if they wish.”

US covid-19 vaccinations to begin Monday as CDC recommends Pfizer vaccine. According to today’s article on Business Insider, “Pfizer and Germany’s BioNTech earlier said they now gather additional data and prepare to file a planned Biologics License Application or BLA with the FDA for a possible full regulatory approval in 2021.”, “The CDC Director accepted the recommendation by CDC’s Advisory Committee on Immunization Practices or ACIP for vaccination with Pfizer-BioNTech COVID-19 vaccine in people 16 years of age and older. ”

Pfizer, biontech covid-19 vaccine candidate study in Germany support safety profile. According to today’s article on MarketWatch, “The study’s result come as the companies’ vaccine is being distributed for use in the U.S. Shares of Pfizer rose 1.5% in premarket trading and BioNTech’s stock gained 0.9%, as futures for the S&P 500 tacked on 0.6%.”, “Pfizer Inc. and its Germany-based partner BioNTech SE said overall results of a Phase 1/2 study in Germany of its COVID-19 vaccine candidate, BNT162b2, mirrored those from the U.S. study. ”

Pfizer, biontech report data from German phase 1/2 trial with covid-19 vaccine candidate. According to today’s article on Business Insider, “Pfizer Inc. (PFE) and BioNTech SE (BNTX) reported additional data on neutralizing antibody and T cell responses from the phase 1/2 trial with BNT162b2 conducted in Germany. “, “BNT162b2 is an investigational COVID-19 vaccine developed by Pfizer-BioNTech. ”

Pfizer’s Sales

Pfizer’s sales growth is a negative 9.7% for the ongoing quarter and a decline by 0.5% for the next. The company’s growth estimates for the present quarter and the next is a negative 9.1% and a negative 8.8%, respectively.

Pfizer’s Revenue

Year-on-year quarterly revenue growth declined by 4.3%, now sitting on 48.65B for the twelve trailing months.

Pfizer’s Stock Top and Bottom Yearly Value

Pfizer’s stock is valued at $39.52 at 14:22 EST, below its 52-week high of $43.08 and way above its 52-week low of $26.45.

Pfizer’s Moving Average

Pfizer’s worth is higher than its 50-day moving average of $37.15 and way higher than its 200-day moving average of $35.17.

Last days news about Pfizer

Netanyahu will be first to get Pfizer vaccine in Israel. According to Bloomberg Quint on Wed Dec 9, “Israeli Prime Minister Benjamin Netanyahu said he’s going to demonstrate his faith in Pfizer Inc.’s coronavirus vaccine by being the first in the country to be inoculated.”

U.k. says those with severe allergy shouldn’t get Pfizer jab. According to Bloomberg Quint on Wed Dec 9, “People with a significant history of allergies should not currently receive the Covid-19 vaccine from Pfizer Inc. and BioNTech SE, the U.K.’s National Health Service said, after two people experienced reactions from the shots.”, “Pfizer and BioNTech said they’re supporting the MHRA in its investigation.”

Head of FDA advisory panel predicts approval for Pfizer vaccine. According to The Wall Street Journal on Wed Dec 9, “”We’re not at the borderline on efficacy,” he added, referring to data from the vaccine’s makers- Pfizer Inc. and Germany’s BioNTech SE-showing the shot is 95% effective at protecting against Covid-19, significantly higher than the 50% minimum the FDA had said would be required for an emergency authorization.”, “The committee has been reviewing the data from Pfizer’s trial since last week.”

Canada approves Pfizer vaccine with first batch due next week. According to Bloomberg Quint on Wed Dec 9, “Canada’s public health authorities approved Pfizer Inc. and BioNTech SE’s Coronavirus vaccine, the first such authorization in a country that’s secured more doses per person than any other around the world.”, “Canada expects to begin receiving next week the first of a batch of 249,000 Pfizer-BioNTech doses, with the order filled partly from facilities in Belgium. ”

Pfizer says some vaccine documents accessed in EMA cyberattack. According to Bloomberg Quint on Wed Dec 9, “Pfizer Inc. said some documents it had submitted to Europe’s top drug regulator regarding its Covid-19 vaccine had been accessed in a cyber-attack on the agency.”, “Both the Pfizer-BioNTech and Moderna two-dose vaccine regimens rely on a new technology known as messenger RNA. ”

First u.s. shipments of Pfizer vaccine will be 2.9 million doses. According to Bloomberg Quint on Wed Dec 9, “Less than half of the available 6.4 million doses of Pfizer Inc.’s Covid-19 vaccine will be initially sent out to states, and 500,000 will be held separately in reserve by the government, according to a top official at Operation Warp Speed.”, “In late November they were told 6.4 million doses of Pfizer’s vaccine candidate would be available at first, and 12.5 million of Moderna Inc.’s shot after it is authorized.”

Pfizer shot gets FDA advisers’ nod as agency decision nears. According to Bloomberg Quint on Thu Dec 10, “Pfizer provided the FDA two months of post-vaccination safety data on clinical trial participants and will provide six months of such data when it applies for full approval of the shot.”, “”We are pleased with the strong majority vote, and if the FDA issues an authorization, stand at the ready to bring this vaccine to people in the U.S. in an effort to help combat this devastating pandemic,” Pfizer Chief Executive Officer Albert Bourla said in a statement.”

Moderna offers U.S. fail-safe on vaccines if Pfizer falls short. According to Bloomberg Quint on Thu Dec 10, “Existing U.S. deals with Pfizer and Moderna for 100 million doses of each company’s vaccine are only enough to inoculate a maximum of 100 million people combined. “, “On Tuesday, a Pfizer board member said that the U.S. government been offered 100 million more doses that could be delivered in the spring, but declined. ”

FDA nears Pfizer decision; Australia cancels order: virus update. According to Bloomberg Quint on Fri Dec 11, “A New York state panel of public-health advisers approved a Food and Drug Administration committee’s backing for emergency use authorization of the Pfizer Inc. and BioNTech SE vaccine, Governor Andrew Cuomo said on Twitter.”, “The U.S. Food and Drug Administration is scrutinizing reports of allergic reactions to Pfizer Inc.’s Covid-19 vaccine as it readies an emergency-use authorization.”

Pfizer vaccine clearance to be sought in Hong Kong after FDA nod. According to Bloomberg Quint on Fri Dec 11, “While Pfizer sought emergency use authorization from the U.K. and U.S., the right to clear the vaccine with regulators in Hong Kong falls with Fosun, under a deal with BioNTech that saw the Chinese drugmaker investing $50 million in the German firm for a 0.7% stake.”, “The Chinese company with the rights to market the Pfizer Inc.-BioNTech SE coronavirus vaccine in Hong Kong is preparing to seek approval of the shot soon after the U.S. clears it, according to people familiar with the matter.”

Pfizer raises quarterly cash dividend to 39 cents a share vs. 38 cents. According to MarketWatch on Fri Dec 11, “Pfizer Inc. said Friday’s its board has raised its quarterly cash dividend to 39 cents a share from 38 cents in the year-earlier period. “, “”It is expected that Viatris will begin paying a quarterly dividend in the second quarter of 2021, at which time Pfizer’s quarterly dividend will be reduced such that the combined dividend dollar amount received by Pfizer shareholders, based upon the combination of continued Pfizer ownership and approximately 0.124079 shares of Viatris which were granted for each Pfizer share in the spin-off, will equate to Pfizer’s dividend amount in effect immediately prior to the initiation of the Viatris dividend,” the company said in a statement. ”

FDA aiming for quick authorization of Pfizer Covid vaccine. According to Bloomberg Quint on Fri Dec 11, “The FDA was encouraged to continue working expeditiously on Pfizer-BioNTech’s EUA request,” Hahn said. “, “An FDA advisory panel voted 17-4, with one abstention, on Thursday that the benefits of Pfizer’s vaccine, which it is developing with BioNTech SE, outweighed any risks.”

Pfizer vaccine cleared in U.S., a landmark in covid-19 fight. According to Bloomberg Quint on Sat Dec 12, “Pfizer has developed special dry-ice containers to make it easier to store for facilities that don’t have the needed equipment.”, “Sanford Health, based in the Upper Midwest, said that it had received notice from Pfizer that its order had been received and that it would be notified when its doses ship.”

Mexico approves Pfizer vaccine for emergency use as covid surges. According to Bloomberg Quint on Sat Dec 12, “Mexico’s health agency Cofepris approved Pfizer’s coronavirus vaccine for emergency use, Deputy Health Minister Hugo Lopez-Gatell said at a press conference Friday night.”, “Mexico joins the U.K., Canada and the U.S. as countries that have granted emergency use of the Pfizer vaccine. ”

Pfizer says prepared to deliver first doses of covid-19 vaccine in U.S. According to Business Insider on Sat Dec 12, “Pfizer and BioNTech said that they are confident in their ability to deliver the vaccine to people in the U.S. Their combined manufacturing network has the potential to supply globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021.”, “Pfizer will have marketing and distribution rights worldwide with the exception of China, Germany, and Turkey.”

U.S. CDC committee of independent health experts recommends vaccination with Pfizer and biontech covid-19 vaccine for persons ages 16 years and older. According to Business Insider on Sat Dec 12, “BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. “, “Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical or clinical trial data and further analyses of existing preclinical or clinical trial data; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations upon commercialization; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when a Biologics License Application for BNT162b2 may be filed in the U.S. and whether and when other biologics license and/or emergency use authorization applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines; whether and when any applications that may be pending or filed for BNT162b2 (including a potential Biologics License Application in the U.S.) may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners or third-party suppliers; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation and attendant storage, distribution and administration requirements, including risks related to handling after delivery by Pfizer; the risk that we may not be able to successfully develop non-frozen formulations; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or have access to logissummary.comtics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain other recommendations from vaccine technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.”


Please enter your comment!
Please enter your name here